Alumis' Acelyrin merger back on track after shareholders unswayed by activist investor
Acelyrin’s shareholders have decided to power ahead with a planned merger with immune-mediated disease specialist Alumis despite the best efforts of an activist investor to derail the deal.
Acelyrin’s shareholders have decided to power ahead with a planned merger with immune-mediated disease specialist Alumis despite the best efforts of an activist investor to derail the deal.
